Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318: 918-926.
Published: 5th January 2018
Authors: Giuliano AG, Ballman KV, McCall L, Beitsch P, Brennan MB, Keleman PR et al.
At median follow-up of 9.3 years, the addition of axillary dissection did not improve disease-free (0.85, 95 per cent confidence interval 0.62 to 1.17) or overall survival (0.85, 0 to 1.16) in this study that included 891 women.Pubmed Link
You may also be interested in
Prospective randomized trial of use of in-house prepared low-cost radiopharmaceutical versus commercial radiopharmaceutical for sentinel lymph node biopsy in patients with early stage invasive breast cancer. World J Surg 2018; 42: 1391-1395.
Authors: Agarwal G, Rajan S, Mayilvaganan S, Mishra A, Krishnani N, Gambhir S et al.
Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. EJSO 2017; 43: 672-679.
Authors: Sávolt A, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E et al.